The global population is ageing and this demographic shift has profound effects on haemostasis, notably a progressive tilt ...

Pfizer has launched a second lawsuit against Novo Nordisk over its $9 billion bid for biotech company Metsera. Pfizer accuses ...

Pfizer filed a second lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for biotech ...

Pfizer alleges Novo Nordisk is attempting to "catch and kill" Metsera, a company Pfizer was in the process of acquiring, in an effort to staunch potential competition for Novo Nordisk's own obesity ...

Metsera's shareholders are scheduled to meet on November 13 to decide on Novo Nordisk's offer of around $8.5 billion, while Pfizer had previously offered $7.3 billion.

Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of ...

Novo Nordisk asserts its acquisition of Metsera won't pose antitrust problems as it competes with Pfizer for dominance in the ...

Pfizer Inc. accused Novo Nordisk A/S of trying to stifle competition in the weight-loss market by attempting to acquire obesity startup Metsera Inc., the second lawsuit Pfizer has filed in four days ...

Pfizer has now filed a suit in federal court, following its claim in state court on Friday. It is riding Trump-era political currents in its efforts to save the deal.

Asian stocks were set to gain Tuesday, tracking advances on Wall Street as Amazon.com Inc.’s $38 billion deal with OpenAI reignited enthusiasm for artificial-intelligence shares.

Pfizer Inc. accused Novo Nordisk A/S of trying to stifle competition in the weight-loss market by attempting to acquire obesity startup Metsera Inc., the second lawsuit in four days as Pfizer tries to ...

Pfizer's lawsuits target Metsera, its directors, and Novo Nordisk for breach of contract and antitrust violations, focusing on Novo Nordisk's acquisition proposal. The first lawsuit claims Novo ...